Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) EBIT (2020 - 2021)

Design Therapeutics' EBIT history spans 2 years, with the latest figure at -$11.1 million for Q4 2021.

  • For Q4 2021, EBIT fell 188.19% year-over-year to -$11.1 million; the TTM value through Dec 2021 reached -$35.8 million, down 330.14%, while the annual FY2025 figure was -$79.5 million, 27.39% down from the prior year.
  • EBIT for Q4 2021 was -$11.1 million at Design Therapeutics, up from -$11.3 million in the prior quarter.
  • Across five years, EBIT topped out at -$623000.0 in Q1 2020 and bottomed at -$11.3 million in Q3 2021.